個人簡介：

Mary Chaohong Hu Biography:

Dr. Mary Chaohong Hu is founder and CEO of Shanghai Miracogen Inc. developing monoclonal antibodies and antibody drug conjugates for cancer therapeutics. She received her BS in Biochemistry from Wuhan University and Ph.D. in Molecular Biology from the Institute of Biophysics, Chinese Academy of Sciences in Beijing, China. She completed her postdoctoral training at the University of Washington, Seattle, Washington.?

She has over 17 years of experience working in the biopharmaceutical/ biotech industry in the US. Before moving back to China, she was Director of Bioassay Development and Process Analytics at Seattle Genetics for development of monoclonal antibodies and antibody-drug conjugates. Prior to joining Seattle Genetics, she was Director of Molecular Biology and Clinical Immunology at GSK /ID Biomedical Corporation and was responsible for preclinical and clinical development of infectious disease vaccines.

公司簡介：

上海美雅珂生物技術有限責任公司為中外合資創辦，成立于2014年初，選址在人才濟濟的上海浦東張江高科技園區，目前建有一千五百平米的辦公區和潔凈實驗區，配備高端生物醫藥人才和世界一流的生物制藥儀器設備。

公司致力于癌癥靶向治療新藥 – 世界前沿技術抗體偶聯藥物（Antibody Drug Conjugate，ADC）的研發、臨床研究及產業化。公司分別在2017年8月和2018年5月獲得兩個自主研發的創新ADC藥物的CFDA臨床批件，并已開展或啟動I期臨床研究；公司在2018年7月申報了第三個創新ADC藥物的IND臨床申請；后續多個靶向新藥也將以每年一個IND申報的進展速度推進。目前開發的多個靶向治療ADC新藥主要涵蓋結直腸癌、食管癌、肺癌、乳腺癌、胃癌和淋巴癌等治療領域。

公司核心管理團隊成員來自于美國GSK, Seattle Genetics等著名跨國生物制藥企業，具有數十年豐富的生物制藥研發、臨床研究、全球法規注冊和GMP生產的經驗。

公司官網：www.miracogen.com.cn